Die kostenlosen ARIVA.DE Börsen-Dienste:
Bleiben Sie immer informiert und melden Sie sich jetzt für die Newsletter von ARIVA.DE an!
Jetzt kostenlos abonnieren

Investor 2022: Prickly Pear

Cashbestand:
67,34 €
Platz:
Gesamtwert mit Cash:
40.347,95 € (15.01.23 06:28)
Börsenspiel beendet. Diese Werte werden nicht mehr aktualisiert.
Kurse zum Spielende    

News

Zeit
Titel
Wertpapier
 
30.05.24 Genprex to Present at the 2024 BIO International Convention
Genprex Inc
14.05.24 Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex Inc
13.05.24 Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
Genprex Inc
08.05.24 Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
Genprex Inc
01.05.24 Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
Genprex Inc
09.04.24 Didi und GAC wollen selbstfahrende Elektro-Robotaxis in Massen in China einführen
DiDi Global
09.04.24 Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Genprex Inc
03.04.24 Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex Inc
02.04.24 Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Genprex Inc
22.03.24 Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Inc
19.03.24 Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Inc
19.03.24 Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Inc
12.03.24 DADA DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Dada Nexus Limited Investors With Losses in Excess of $100k to Secure Counsel Before Important March 11 Deadline in Securities Class Action First Filed by the Firm - DADA
Dada Nexus
12.03.24 Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Genprex Inc
11.03.24 SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Dada Nexus Limited - DADA
Dada Nexus
11.03.24 Dada Nexus Limited Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - DADA
Dada Nexus
08.03.24 DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
Dada Nexus
07.03.24 DADA LAWSUIT ALERT: The Gross Law Firm Notifies Dada Nexus Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Dada Nexus
06.03.24 DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
Dada Nexus
06.03.24 CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises DADA NEXUS (NASDAQ: DADA) Investors to Inquire About a Securities Fraud Class Action by March 11, 2024
Dada Nexus
06.03.24 Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Genprex Inc
06.03.24 Dada Nexus Limited Class Action: Levi & Korsinsky Reminds Dada Nexus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 11, 2024 - DADA
Dada Nexus
05.03.24 DADA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Dada Nexus Limited Investors to Secure Counsel Before Important March 11 Deadline in Securities Class Action First Filed by the Firm - DADA
Dada Nexus
05.03.24 ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Dada
Dada Nexus
03.03.24 DADA DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Dada Nexus Limited Investors to Secure Counsel Before Important March 11 Deadline in Securities Class Action First Filed by the Firm - DADA
Dada Nexus
03.03.24 SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Dada Nexus Limited - DADA
Dada Nexus
01.03.24 DADA NEXUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dada Nexus Limited - DADA
Dada Nexus
01.03.24 DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
Dada Nexus
29.02.24 SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Dada
Dada Nexus
27.02.24 Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 11, 2024 in Dada Nexus Limited Lawsuit - DADA
Dada Nexus
30.05.24
Genprex Inc
Genprex to Present at the 2024 BIO International Convention
14.05.24
Genprex Inc
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
13.05.24
Genprex Inc
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
08.05.24
Genprex Inc
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
01.05.24
Genprex Inc
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
09.04.24
DiDi Global
Didi und GAC wollen selbstfahrende Elektro-Robotaxis in Massen in China einführen
09.04.24
Genprex Inc
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
03.04.24
Genprex Inc
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
02.04.24
Genprex Inc
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
22.03.24
Genprex Inc
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19.03.24
Genprex Inc
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19.03.24
Genprex Inc
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12.03.24
Dada Nexus
DADA DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Dada Nexus Limited Investors With Losses in Excess of $100k to Secure Counsel Before Important March 11 Deadline in Securities Class Action First Filed by the Firm - DADA
12.03.24
Genprex Inc
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
11.03.24
Dada Nexus
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Dada Nexus Limited - DADA
11.03.24
Dada Nexus
Dada Nexus Limited Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - DADA
08.03.24
Dada Nexus
DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
07.03.24
Dada Nexus
DADA LAWSUIT ALERT: The Gross Law Firm Notifies Dada Nexus Limited Investors of a Class Action Lawsuit and Upcoming Deadline
06.03.24
Dada Nexus
DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
06.03.24
Dada Nexus
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises DADA NEXUS (NASDAQ: DADA) Investors to Inquire About a Securities Fraud Class Action by March 11, 2024
06.03.24
Genprex Inc
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
06.03.24
Dada Nexus
Dada Nexus Limited Class Action: Levi & Korsinsky Reminds Dada Nexus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 11, 2024 - DADA
05.03.24
Dada Nexus
DADA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Dada Nexus Limited Investors to Secure Counsel Before Important March 11 Deadline in Securities Class Action First Filed by the Firm - DADA
05.03.24
Dada Nexus
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Dada
03.03.24
Dada Nexus
DADA DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Dada Nexus Limited Investors to Secure Counsel Before Important March 11 Deadline in Securities Class Action First Filed by the Firm - DADA
03.03.24
Dada Nexus
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Dada Nexus Limited - DADA
01.03.24
Dada Nexus
DADA NEXUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dada Nexus Limited - DADA
01.03.24
Dada Nexus
DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
29.02.24
Dada Nexus
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Dada
27.02.24
Dada Nexus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 11, 2024 in Dada Nexus Limited Lawsuit - DADA
Musterdepot - © Ismagilov / Shutterstock

Das kostenlose Musterdepot von ARIVA.DE

Bei einem niedrigen Kurs einsteigen, bei einem hohen Kurs wieder verkaufen – es klingt einfach, an der Börse Erfolg zu haben. Tatsächlich brauchen Aktionäre gute Nerven, wenn die Kurse auf und ab schwanken. Realistische Anlageziele, eine klare Linie bei der Auswahl der Wertpapiere und das clevere Einsetzen bestimmter Ordertypen gehören zum Handwerk beim Handel mit Wertpapieren.

Um ein Gefühl dafür zu bekommen, welche Strategien in welchen Börsenphasen fruchten, können Nutzerinnen und Nutzer bei ARIVA.DE kostenlos ein Musterdepot anlegen und Wertpapiere wie Anleihen, Aktien, Derivate oder Fonds virtuell im Musterdepot handeln. Die Orders werden zum Schein ausgeführt und finden sich dann in einem virtuellen Musterdepot, ohne dass die Papiere tatsächlich ge- oder verkauft werden. So lassen sich Anlagestrategien testen, ohne Geld zu riskieren.

Viele Nutzer bauen auf ARIVA.DE im Musterdepot ihr reales Depot nach, das ein Broker für sie führt. Grund: Beim Musterdepot auf ARIVA.DE ist jede Position mit den zugehörigen News, dem Forum und der Profilseite verlinkt. Über die Aktien auf dem Laufenden zu bleiben, ist durch das Musterdepot sehr einfach. Möglich ist es auf ARIVA.DE auch, interessante Wertpapiere in eine Watchlist aufzunehmen, um ihre Entwicklung im Auge zu behalten. Nutzer können dabei Kursgrenzen vorgeben und sich bei Erreichen benachrichtigen lassen.

Übrigens: Wer ein virtuelles Musterdepot im Rahmen eines der Börsenspiele von ARIVA.DE eröffnet, hat einen weiteren Lerneffekt: Beim Börsenspiel wird ein Budget vorgegeben, und für jede Transaktion fallen virtuelle Gebühren an. Das macht den „Scheinhandel“ noch realistischer.